Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convert...( Single Institutional Investor ...),Health

Single Institutional Investor Purchases $9MM Convertible Notes

NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq: CTICD, and MTA: CTIC) today announced that a single institutional investor has agreed to purchase, for $9 million, newly issued 10% Convertible Senior Notes due 2012, with a conversion price of $1.27 per share. The Company has a put right subject to price, volume and other requirements exercisable no later than October 15, 2008 for the same institutional investor to purchase an additional $9 million of 10% Series B Convertible Senior Notes due in 2012.

The new Notes, and the follow-on Notes would similarly have a $9 million initial principal balance and feature a make-whole provision entitling the holder, upon any conversion of the Notes, to receive the interest payable through scheduled maturity, less any interest paid before conversion. The Company expects to receive net proceeds of approximately $5.4 million from the Notes (before payment of fees and expenses), after depositing amounts in escrow for the make-whole provision. The Notes will rank equal in right of payment with all existing and future unsecured senior indebtedness of the Company.

Pursuant to the note agreement, CTI shall make a payment in the amount of $150,000 as an inducement for the investor and its affiliates to convert 1,000 shares of Series C Preferred Stock owned by the investor into Common Stock of the Company pursuant to the provisions of the Company's articles of incorporation. In connection with this securities transaction, CTI shall also make a payment to the investor and its affiliates in the amount of $1,225,000 in exchange for the prospective satisfaction of 50% of any
'/>"/>